Are We HER-ting for Innovation in Neoadjuvant Breast Cancer Trial Design?

Breast Cancer Research - United Kingdom
doi 10.1186/bcr2209
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Comparison of the Efficacy and Survival Analysis of Neoadjuvant Chemotherapy for Her-2-Positive Breast Cancer

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2018English

Are We Missing the mTOR Target in Breast Cancer?

Breast Cancer Research and Treatment
Cancer ResearchOncology
2010English

Neoadjuvant Chemotherapy in Breast Cancer

English

Target HER Four in Breast Cancer?

Oncotarget
Oncology
2019English

Neoadjuvant Chemotherapy: Role in Breast Cancer

2013English

Neoadjuvant Systemic Therapy in Breast Cancer

2012English

Breast Cancer Research: Where We Are and Where We Should Go

Breast Cancer Research
Cancer ResearchOncology
2000English

Neoadjuvant Chemotherapy for Early Breast Cancer – Author's Reply

The Lancet Oncology
Oncology
2018English

Clinical Experience of Dual Targeted Blockade (Pertuzumab + Trastuzumab + Docetaxel) in Neoadjuvant Therapy of Early HER-2-Positive Breast Cancer

Effective Pharmacotherapy
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy